axial spondyloarthritis

World AS Day 2024 - spotlighting the signs and symptoms of axial spondyloarthritis (axSpA): How ��ֳ� works with the axSpA community

Vandenbruaene Nathalie — Fri, 03 May 2024 12:12:03 +0000

World AS Day 2024 - spotlighting the signs and symptoms of axial spondyloarthritis (axSpA): How ��ֳ� works with the axSpA community

Zsófia Bakonyi, Patient Strategy Rheumatology

Vandenbruaene … Fri 03/05/2024 - 14:12

On World AS Day 2024, ��ֳ� reaffirms its commitment to supporting people living with axial spondyloarthritis (axSpA). This year's theme, "Signs and Symptoms", highlights the importance of early recognition and diagnosis, to positively impact the lives of those affected by this chronic inflammatory disease through effective collaborations.

We are proud to work with organizations like the Axial Spondyloarthritis International Federation (ASIF) to raise awareness of AS to educate and engage patients and to support rheumatologists through medical education initiatives. axSpA can be very painful, with a significant, limiting impact on people’s mobility – yet the average time to diagnosis isn’t until seven years after symptom onset. Common symptoms include back pain, fatigue, stiffness worsening after inactivity, and associated conditions like uveitis, psoriasis, and inflammatory bowel disease. Empowering patients to recognize and talk to their healthcare providers (HCPs) about these symptoms may help lead to earlier diagnoses and disease control, helping to prevent irreversible structural damage.

Through research, partnerships, and medical education, ��ֳ� strives to reduce the diagnostic delay for axSpA globally, acting on the findings of ASIF’s global ‘Delay to Diagnosis’ report. We will do this with partners like the UK’s National Axial Spondyloarthritis Society (NASS), through comprehensive public outreach and working with clinicians on axSpA MRI training programs, aiming to achieve their ambition of a ‘Gold Standard’ time to diagnosis of just one year for axSpA by 2025.

We are addressing other gaps in the rheumatology patient journey by supporting physicians through digital health platforms. In our FASTRAX program, we use new technologies to educate healthcare providers, with ambitions to reduce instances of primary care physicians not recognizing inflammatory pain; to prevent people living with axSpA from being lost through incorrect assessment and triage; and to improve access to expert rheumatology care.

Our Europe-wide Rheumacensus program is leading the way in elevating the standard of care for patients with axSpA by highlighting unmet care needs. We collaborate with HCPs, payors and patients themselves to gain a holistic view of the situation in rheumatology care and have reached consensus on areas requiring improvement. The results from this program have recently been published in Rheumatology and Therapy, laying a framework for rheumatologists to make real, positive changes in their clinics.

For HCPs specifically, we work with clinical experts to create a wealth of medical education resources like RheuMuseum, to support awareness of the clinical manifestations of axSpA among US HCPs, and the ��ֳ� Med Hub, a specialized platform that makes it easy for HCPs to stay aware of the latest advancements in immunology and find ready-to-use resources for their day-to-day practice.

On World AS Day and every day, ��ֳ� remains dedicated to serving the axSpA community through pioneering research, raising disease awareness, and amplifying patient voices.

solutions

311 Likes

Transforming rheumatology

Vanco Vlastimil (��ֳ� S.A.) — Fri, 12 May 2023 07:00:00 +0000

Transforming rheumatology

Athanasia Gkiouleka, Rheumatology Mission

Vanco Vlastimi… Fri 12/05/2023 - 09:00

At ��ֳ�, we embrace the possibility to transform the lives of people living with psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), systemic lupus erythematosus (SLE) and osteoporosis.

Despite the progress made in recent years, there remains a significant unmet need for people living with rheumatic diseases. We are hopeful, however, that the solid foundation established in partnership with the scientific community provides the opportunity to elevate care for people living with rheumatic diseases, allowing them to live as free as possible from the challenges and uncertainty caused by their disease.

Building on more than 30 years of research, we are now exploring approaches to move from symptomatic treatment to disease modification and cure. Our evolving rheumatology portfolio gives us the potential to deliver and expand value for numerous patient populations, including those living with axSpA, PsA and osteoporosis.

Through our unique mix of expertise, innovation and ambition, we aim to pioneer and accelerate scientific advancements which make a meaningful difference to people living with rheumatic diseases. Have a look at the infographic below to learn how ��ֳ� is aiming to transform rheumatology.

Inspired by patients, driven by science, we are ��ֳ�.

To learn more about ��ֳ�’s commitment to people living with rheumatic diseases, visit www.ucb.com/disease-areas

about ucb

rheumatology psoriatic arthritis axial spondyloarthritis Systemic lupus erythematosus osteoporosis

436 Likes

EULAR 2022: ��ֳ� unites with the community to share the latest scientific breakthroughs and clinical research in rheumatology

Vandenbruaene Nathalie — Wed, 01 Jun 2022 08:56:30 +0000

EULAR 2022: ��ֳ� unites with the community to share the latest scientific breakthroughs and clinical research in rheumatology

John Ioannou, Medical Affairs, Rheumatology

Vandenbruaene … Wed 01/06/2022 - 10:56

As an organisation, we always feel a great sense of pride when ��ֳ� takes part in the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology, and this year feels extra special. EULAR is celebrating an impressive milestone – its 75th anniversary – and the congress is being held as a hybrid congress for the very first time.

Thousands of delegates from across the world will be coming together both virtually and on-site in Copenhagen, Denmark. The opportunity to connect virtually for the last two years has been invaluable, however, being able to meet with some of our friends and colleagues in person for scientific exchange is something I am sure we are all looking forward to.

At this year’s congress, ��ֳ� will be sharing a wealth of new and important clinical data. In particular, we are proud to be sharing the first presentations of our pivotal Phase 3 data from our extensive research programmes in psoriatic arthritis and axial spondyloarthritis. The depth of our research programmes is testimony to our continuing commitment to delivering real value for people living with these conditions.

In addition, our three sponsored scientific symposia will bring the rheumatology community together to discuss and debate ‘Raising the Target for Patients Living with Psoriatic Arthritis’, ‘Raising the Target for Patients Living with Axial Spondyloarthritis’ and ‘Evolving Concepts in axSpA-2022 Update’. To enhance scientific exchange, we are also pleased to support a ‘Consult the Expert’ session focused on enthesitis management. We look forward to continuing discussions around the latest advancements in the rheumatology field at our exhibition booth, where members of our ��ֳ� team will be ready and pleased to welcome all those in attendance.

We are honoured to be partnering with our esteemed colleagues and peers to drive the future of rheumatology at this year’s congress. We look forward to being a part of EULAR 2022!

You can stay up to date on the latest ��ֳ� news at EULAR 2022 through our social media channels (Twitter, LinkedIn).

about ucb

EULAR Rheumatology psoriatic arthritis axial spondyloarthritis

469 Likes

��ֳ� Recognizes World Arthritis Day 2020

eCMSadmin — Mon, 12 Oct 2020 08:30:00 +0000

��ֳ� Recognizes World Arthritis Day 2020

Andrea Christopher, Global Communications & Company Reputation

eCMSadmin Mon 12/10/2020 - 10:30

Today we are shining a light on World Arthritis Day in efforts to raise awareness of patients living with rheumatic and musculoskeletal diseases (RMDs), including rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), as part of ��ֳ�’s ongoing commitment to the rheumatology community.

��ֳ� has been proudly leading the way in connecting innovative science to unmet needs in specific patient populations, such as women of childbearing age and patients with axSpA and PsA. We are committed to providing a transformative experience for these patients.

As we lean into ��ֳ�’s Accelerate & Expand phase, it is our ambition to lead the way in providing holistic solutions that address patient needs at all key milestones in their healthcare journey.

Our innovative research in axSpA and PsA has laid a solid foundation to help us achieve our future vision for meeting the needs of these patients. There is great opportunity to innovate and improve care for patients with axSpA, starting with earlier and more accurate diagnoses.

Additionally, with the launch of the Advantage Hers campaign last month, we are continuing to highlight the unmet needs and unique challenges of women living with rheumatic diseases and other chronic inflammatory conditions.

Furthermore, we are empowering and equipping these patients to have informed conversations with their specialist about creating a management plan that is best tailored to their individual needs.

World Arthritis Day, led by the European League Against Rheumatism (EULAR), aims to help people living with RMDs avoid long-term complications by improving education of the condition, promoting early diagnosis and encouraging access to care.

EULAR’s campaign theme ‘Don’t Delay, Connect Today,’ calls on the public, physicians, policymakers and health professionals to connect and diagnose RMDs earlier and provide timely access to evidence-based treatment.

RMDs impact hundreds of millions of people worldwide and predominantly affect a person’s joints, muscles and connective tissues, causing pain and loss of physical function.

Today, and every day, ��ֳ� remains dedicated to providing innovative solutions to people living with these diseases and to raising public awareness of the importance of early diagnosis and available treatment options.

solutions

World Arthritis Day 2020 rheumatic diseases psoriatic arthritis musculoskeletal diseases axial spondyloarthritis Advantage Hers

734 Likes

Inflammatory diseases: Big news on small molecules

eCMSadmin — Tue, 04 Feb 2020 14:00:00 +0000

Inflammatory diseases: Big news on small molecules

James O’Connell, Research & Early Development

eCMSadmin Tue 04/02/2020 - 15:00

��ֳ� has been a leader in biological therapies for inflammatory conditions, including rheumatoid arthritis. Now, our scientists have unveiled a discovery that could build on our small molecule heritage in medicinal chemistry – and open the door to a new wave of therapies for people with serious conditions.

TNF is a protein known to play a key role in inflammation. The development of biological therapies that block or inhibit TNF paved the way for a range of therapies that improved the lives of people with rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis.

Take rheumatoid arthritis, for example. ��ֳ� has played an important role in bringing monoclonal antibodies – which are a leading form of anti-TNF medication – to many patients around the world. By inhibiting TNF activity, inflammation can be significantly reduced. This eases patients’ symptoms and can spare them irreparable damage to their joints.

This was a major breakthrough for medical science in the late 20th century. For decades, researchers searched for ‘small molecules’ that could disrupt TNF activity and give patients the relief they needed. Despite the best efforts of the scientific community, it appeared that small molecules (pills) could not deliver the effect required. Monoclonal antibodies (injectables), which are much larger molecules, changed everything.

However, the idea of small molecules that could affect TNF activity never went away. These elusive compounds were considered to be ‘high-hanging fruit’ in the scientific community, but there is good reason to pursue this Holy Grail.

Small molecules offer several advantages over larger biological therapies:, they can be taken orally which is convenient for patients, and they have shorter half-lives – which is beneficial to patients that need to stop taking their medication quickly.

They also have potential to cross the blood-brain barriers which could allow doctors to treat inflammatory diseases of the central nervous system. For example, inflammation may play a role in neurodegenerative conditions.

��ֳ� was founded more than 90 years ago and made its mark in medical science by focusing on small molecules. Biological therapies are now a key component of our effort to improve the lives of patients, but our small molecule expertise remains. This experience and our active interest in autoimmune diseases inspired our scientists to explore new ways in which small molecules could influence TNF.

A new paper, published in Nature Communications by 16 current and former ��ֳ� scientists, unveils an important step forward in this quest. They describe the first ever genuine small molecule antagonist of TNF. This could be the beginning of another new chapter for people living with inflammatory diseases for which there are currently no oral anti-TNF medicines available.

For the first time we have been able to show that TNF-receptor interactions can be tackled with small molecules, not by taking on the interface where the partners interact, (which would be impossible), but by locking one of the partners in a signaling-incompetent state. We discovered that TNF naturally moves and flips between different conformations all the time; some of these are biologically active, and some aren’t. We took advantage of this understanding to design small chemical compounds which bind to these moving targets and restrict the movement to ensure clinically-desired outcomes. It’s like using a grain of sand (small molecule) in the hinge of a door, rather than your arm (biologic), to stop it swinging. This new thinking makes these targets druggable using medicinal chemistry that has been applied to targets such as enzymes for a hundred years.

We are delighted that a broad team effort has delivered this entirely new advance in medical science and hope to see this science translated into life-changing therapies for people in need.

innovation

Rheumatoid arthritis TNF small molecules psoriatic arthritis psoriasis Nature Communication inflammation axial spondyloarthritis

571 Likes

axial spondyloarthritis

World AS Day 2024 - spotlighting the signs and symptoms of axial spondyloarthritis (axSpA): How ��ֳ� works with the axSpA community

Leave a Comment

Transforming rheumatology

Leave a Comment

EULAR 2022: ��ֳ� unites with the community to share the latest scientific breakthroughs and clinical research in rheumatology

Leave a Comment

��ֳ� Recognizes World Arthritis Day 2020

Leave a Comment

Inflammatory diseases: Big news on small molecules

Leave a Comment

axial spondyloarthritis

World AS Day 2024 - spotlighting the signs and symptoms of axial spondyloarthritis (axSpA): How ������ֳ� works with the axSpA community

Leave a Comment

Transforming rheumatology

Leave a Comment

EULAR 2022: ������ֳ� unites with the community to share the latest scientific breakthroughs and clinical research in rheumatology

Leave a Comment

������ֳ� Recognizes World Arthritis Day 2020

Leave a Comment

Inflammatory diseases: Big news on small molecules

Leave a Comment

World AS Day 2024 - spotlighting the signs and symptoms of axial spondyloarthritis (axSpA): How ��ֳ� works with the axSpA community

EULAR 2022: ��ֳ� unites with the community to share the latest scientific breakthroughs and clinical research in rheumatology

��ֳ� Recognizes World Arthritis Day 2020